Expertise in
16
conditions

Dr. Tyler C. Gunter

Oncology
Ou Health Stephenson Cancer Center-Radiation Therapy
800 NE 10th St # L100, 
Oklahoma City, OK 
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
Ou Health Stephenson Cancer Center-Radiation Therapy
800 NE 10th St # L100, 
Oklahoma City, OK 

Overview

Tyler Gunter is an Oncologist practicing medicine in Oklahoma City, Oklahoma.

Dr. Gunter is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and Brain Tumor.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 10 clinical trials. Dr. Gunter is currently accepting new patients.

Specialties

Oncology

Hospital Affiliations

Oklahoma Heart Hospital, LLC
Norman Regional
O U Medical Center
Mcalester Regional Health Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Ou Health Stephenson Cancer Center-Radiation Therapy
800 NE 10th St # L100, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Carboplatin, Paclitaxel, FOLFOX regimen, CAPOX regimen, Docetaxel, 5FU
Study Phase: Phase 3
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: May 20, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
View 9 Less Clinical Trials

10 Total Publications

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
Journal: BMJ open
Published: April 24, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic

800 NE 10th St Ste 2100, 
Oklahoma City, OK 
 (0.4 miles away)
405-271-8707
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joan Walker is an Oncologist practicing medicine in Oklahoma City, Oklahoma. She has been practicing medicine for over 44 years. Dr. Walker is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Gamma Knife Radiosurgery, and Ureteroscopy. Dr. Walker is currently accepting new patients.

Expertise in
53
conditions
Expertise in
53
conditions
Referral may be required

SSM Health Cancer Care

3525 N.W. 56th St., Suite 100D, 
Oklahoma City, OK 
 (5.9 miles away)
405-942-9200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Board certified in both medical oncology and internal medicine, Aleda Toma, MD is a member of Cancer Specialists of Oklahoma, a part of SSM Health St. Anthony. She cares for patients in north Oklahoma City and surrounding areas, as well as Shawnee, Okla. Dr. Toma is highly rated in 53 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Toma is board certified in Oklahoma State Board Of Medical Licensure & Supervision, American Board Of Internal Medicine/Medical Oncology , American Board Of Internal Medicine , Drug Enforcement Administration , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . Dr. Toma is currently accepting new patients.

Expertise in
80
conditions
Expertise in
80
conditions
Referral may be required

Mercy Hospital Oklahoma City Inc.

4300 W Memorial Rd, 
Oklahoma City, OK 
 (10.6 miles away)
405-751-4343
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Keefer is an Oncologist practicing medicine in Oklahoma City, Oklahoma. Dr. Keefer is highly rated in 80 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Chondrosarcoma, Ewing Sarcoma, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Keefer is currently accepting new patients.

Frequently Asked Questions about Dr. Tyler C. Gunter

How do I make an appointment with Dr. Tyler C. Gunter?

You can book an appointment with Dr. Tyler C. Gunter by calling their office at 405-271-5641. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tyler C. Gunter a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tyler C. Gunter is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tyler C. Gunter specialize in?

While Dr. Tyler C. Gunter is a Oncology, they have specific expertise in Prostate Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Tyler C. Gunter participate in research or clinical trials?

Yes. Dr. Tyler C. Gunter has published 10 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Tyler C. Gunter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tyler C. Gunter accept my insurance?

Dr. Tyler C. Gunter accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 405-271-5641 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunter's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile